TickerFacts.

Cytosorbents Corp (CTSO): R&D Expense

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2016-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

Older than the company's other figures. The latest R&D Expense is for the year ended 2023-12-31, while the company's latest annual report covers the year ended 2025-12-31. Its later filings do not report this line under the concept TickerFacts maps.

$15.73M
Year ended 2023-12-31
+21.3%
3-year compound annual growth
+15.3%
5-year compound annual growth
$16.38M2010-12-31: $1.76M2011-12-31: $2.89M2012-12-31: $2.53M2013-12-31: $1.74M2014-12-31: $2.43M2015-12-31: $3.87M2016-12-31: $4.07M2017-12-31: $3.22M2018-12-31: $7.72M2019-12-31: $12.09M2020-12-31: $8.81M2021-12-31: $16.38M2022-12-31: $15.12M2023-12-31: $15.73M$15.73M
2010-12-31 R&D Expense (USD) 2023-12-31
Period endedR&D ExpenseChange YoYSource filing
2023-12-31$15.73M+4.0%2024-03-15, From 2023-01-01
2022-12-31$15.12M-7.7%2024-03-15, From 2022-01-01
2021-12-31$16.38M+85.9%2024-03-15, From 2021-01-01
2020-12-31$8.81M-27.1%2023-03-09, From 2020-01-01
2019-12-31$12.09M+56.6%2022-03-10, From 2019-01-01
2018-12-31$7.72M+139.8%2021-03-09, From 2018-01-01
2017-12-31$3.22M-20.9%2020-03-05, From 2017-01-01
2016-12-31$4.07Mn/c2019-03-07, From 2016-01-01
2015-12-31$3.87M+59.2%2018-03-08, From 2015-01-01
2014-12-31$2.43M+39.8%2017-03-03, From 2014-01-01
2013-12-31$1.74M-31.3%2015-03-31, From 2013-01-01
2012-12-31$2.53M-12.3%2014-03-31, From 2012-01-01
2011-12-31$2.89M+64.4%2013-04-03, From 2011-01-01
2010-12-31$1.76Mn/a2012-03-30, From 2010-01-01